These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34131897)

  • 1. Time to rethink haemoglobin threshold guidelines in sickle cell disease.
    Ballas SK; Kuypers FA; Gordeuk VR; Hankins JS; Thompson AA; Vichinsky E
    Br J Haematol; 2021 Nov; 195(4):518-522. PubMed ID: 34131897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
    Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
    Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM
    Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794
    [No Abstract]   [Full Text] [Related]  

  • 6. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor?
    Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD
    Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770
    [No Abstract]   [Full Text] [Related]  

  • 9. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
    Ataga KI; Staffa SJ; Brugnara C; Stocker JW
    Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
    Ershler WB; Holbrook ME
    Transfusion; 2020 Dec; 60(12):3066-3067. PubMed ID: 32815179
    [No Abstract]   [Full Text] [Related]  

  • 12. Two drugs for sickle cell disease.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
    [No Abstract]   [Full Text] [Related]  

  • 13. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
    Çanak B; Eşkazan AE
    Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies.
    Sánchez LM; Morrone K; Frei-Jones M; Fasipe TA
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e277-e283. PubMed ID: 38718300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
    Inusa BPD; Mnika K; Babiker S
    Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational agents for sickle cell disease.
    Okpala I
    Expert Opin Investig Drugs; 2006 Aug; 15(8):833-42. PubMed ID: 16859388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating sickle cell anemia: A new era dawns.
    Steinberg MH
    Am J Hematol; 2020 Apr; 95(4):338-342. PubMed ID: 31925819
    [No Abstract]   [Full Text] [Related]  

  • 20. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.